Biopharmaceutical makers, academic institutions, patient groups and government agencies facing complex scientific, regulatory or other challenges whose solutions are beyond the reach of a single entity can benefit by leveraging and aggregating their…
written on 30.06.2014
US Capitol Capsule: Consortia tide rising: Does it float your boat?
